Explain this page
Arphra AIPlain-English read on Natera, Inc.’s valuation06-12today
- NCCN Recommends ctDNA-MRD Testing Using Signatera™ Technology in Landmark Bladder Cancer Guideline Update19h
- NCCN Recommends ctDNA-MRD Testing Using Signatera™ Technology in Landmark Bladder Cancer Guideline Update19h
- Natera to Showcase Organ Health Leadership with 21 Presentations at the American Transplant Congress5d
- Natera to Showcase Organ Health Leadership with 21 Presentations at the American Transplant Congress5d
AI Issuer Brief
Arphra AILoading cached brief…
Fair value
Football field →Weighted blend
—
— vs spot
Recommendation
n/a
0 of 0 methods
Method spread
0bull0bear
±5% threshold
Analyst PT consensus: $258.00 (+9.90%)
Candlestick · 1Y
Open in chart workstation →NTRA
231.41+34.64%H 256.36L 131.81MA50 207.88MA200 206.57Avg vol 1.3M
Price change · trailing returns
Live| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +2.60% | +0.91% | +15.54% | +17.33% | -0.27% | +2.48% | +37.79% | +357.00% | +104.21% | +1623.64% | +1204.22% |
Insider · 30d
History →Bought
$0
0 txns
Sold
$2.01M
10 txns
Net flow
−$2.01M
Aftermarket
LiveLast trade
$236.76
35 sh
Bid
$225.00
1 sh
Ask
$243.00
26 sh
Spread
$18.000
Recent quarters
All financials →| Period | Revenue | Net income | EPS |
|---|
Sector & industry today
LiveSectors
- Technology+2.51%
- Industrials+1.00%
- Basic Materials+0.65%
- Energy+0.59%
- Financial Services+0.23%
- Healthcare-0.18%
- Communication Services-0.18%
- Consumer Defensive-0.30%
- Consumer Cyclical-0.85%
- Real Estate-0.99%
- Utilities-1.03%
Top industries (issuer's industry highlighted)
- Medical - Diagnostics & Research+0.68%
- Software - Services+9.60%
- Broadcasting+8.34%
- Medical - Equipment & Services+5.08%
- Computer Hardware+4.56%
- Financial - Mortgages+4.08%
- Staffing & Employment Services-3.62%
- Internet Content & Information+3.58%
- Coal-3.56%
- Oil & Gas Energy-3.54%
- Biotechnology+3.28%
- Electrical Equipment & Parts+3.27%
Analyst view
Consensus target
—
No price-target data returned for this ticker.
Recent actions
0 ↑0 ↓0 hold
- No recent grade actions.
News
DB · news_items- NCCN Recommends ctDNA-MRD Testing Using Signatera™ Technology in Landmark Bladder Cancer Guideline Updatebusinesswire.com·Jun 23, 2026
- NCCN Recommends ctDNA-MRD Testing Using Signatera™ Technology in Landmark Bladder Cancer Guideline Updatebusinesswire.com·Jun 23, 2026
- Natera to Showcase Organ Health Leadership with 21 Presentations at the American Transplant Congressbusinesswire.com·Jun 18, 2026
- Natera to Showcase Organ Health Leadership with 21 Presentations at the American Transplant Congressbusinesswire.com·Jun 18, 2026
- Natera, Inc. (NTRA) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcriptseekingalpha.com·Jun 12, 2026
- NTRA & CytoDyn Partner to Advance ctDNA-Guided Development in mCRCzacks.com·Jun 08, 2026
- Natera and CytoDyn Announce Strategic Collaboration to Advance ctDNA-Guided Development and Molecular Response Analysis in Metastatic Colorectal Cancerbusinesswire.com·Jun 04, 2026
- Natera and CytoDyn Announce Strategic Collaboration to Advance ctDNA-Guided Development and Molecular Response Analysis in Metastatic Colorectal Cancerbusinesswire.com·Jun 04, 2026
Recent analyst activity
DB- Jun 11, 2026GradeOutperform → OutperformRBC Capital Starts Natera (NTRA) at OutperformRBC Capital
- Jun 11, 2026PT$275.00RBC Capital Starts Natera (NTRA) at OutperformRBC Capital
- Jun 05, 2026GradeNeutralGoldman Sachs Starts Natera (NTRA) at NeutralGoldman Sachs
- Jun 05, 2026PT$245.00Goldman Sachs Starts Natera (NTRA) at NeutralGoldman Sachs
Financial scores
DBJun 23, 2026Altman Z
23.24
Safe
≥ 3.0 safe · 1.81–3.0 grey · < 1.81 distress
Piotroski F
4/9
Average
≥ 7 strong · 4–6 average · < 4 weak
Peers
No peer list available for NTRA.
Total assets
—
Total debt
—
Cash & equiv
—
Operating CF
—
Free cash flow
—
Buybacks
—
Recent insiders
All →| Insider | Action | Shares | Value | Date |
|---|---|---|---|---|
Sheena Jonathan director, other: CO-FOUNDER | Sell | 244 | $54.04K | Jun 17, 2026 |
Sheena Jonathan director, other: CO-FOUNDER | Sell | 301 | $66.64K | Jun 17, 2026 |
Sheena Jonathan director, other: CO-FOUNDER | Sell | 96 | $21.04K | Jun 17, 2026 |
Sheena Jonathan director, other: CO-FOUNDER | Sell | 128 | $28.06K | Jun 17, 2026 |
Sheena Jonathan director, other: CO-FOUNDER | Sell | 256 | $55.84K | Jun 17, 2026 |
Sheena Jonathan director, other: CO-FOUNDER | Sell | 267 | $58.25K | Jun 17, 2026 |
Income statement · annual
5y| Period | Revenue | Op income | Net income | EPS | Net margin |
|---|